Stay updated on Pembrolizumab+Binimetinib+Bevacizumab in Refractory CRC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab+Binimetinib+Bevacizumab in Refractory CRC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab+Binimetinib+Bevacizumab in Refractory CRC Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    No Change Detected
  3. Check
    16 days ago
    Change Detected
    Summary
    The page’s revision/version indicator was updated from v3.5.2 to v3.5.3, reflecting a site release rather than a change to the clinical study details.
    Difference
    0.0%
    Check dated 2026-04-25T18:45:06.000Z thumbnail image
  4. Check
    23 days ago
    Change Detected
    Summary
    Revision updated from v3.5.0 to v3.5.2 on the site.
    Difference
    0.0%
    Check dated 2026-04-18T13:41:24.000Z thumbnail image
  5. Check
    52 days ago
    Change Detected
    Summary
    Revision indicator updated from v3.4.3 to v3.5.0. No study content or eligibility details appear to be affected.
    Difference
    0.0%
    Check dated 2026-03-21T00:52:28.000Z thumbnail image
  6. Check
    66 days ago
    Change Detected
    Summary
    Revision: v3.4.3 is now shown, replacing the previous Revision: v3.4.2.
    Difference
    0.0%
    Check dated 2026-03-06T18:41:30.000Z thumbnail image
  7. Check
    87 days ago
    Change Detected
    Summary
    Revision updated from v3.4.1 to v3.4.2 is reflected on the page. This is a technical update with no substantive changes to study data or displayed information. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-02-13T11:49:46.000Z thumbnail image
  8. Check
    95 days ago
    Change Detected
    Summary
    Page revision updated from v3.4.0 to v3.4.1.
    Difference
    0.0%
    Check dated 2026-02-05T15:15:26.000Z thumbnail image

Stay in the know with updates to Pembrolizumab+Binimetinib+Bevacizumab in Refractory CRC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab+Binimetinib+Bevacizumab in Refractory CRC Clinical Trial page.